These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 18042562)

  • 1. Insurers and 'targeted biologics' for cancer: a conversation with Lee N. Newcomer. Interview by Barbara J. Culliton.
    Newcomer LN
    Health Aff (Millwood); 2008; 27(1):w41-51. PubMed ID: 18042562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoting medical innovation while developing sound social and business policy: a conversation with Thomas G. Roberts. Interview by Barbara J. Culliton.
    Roberts TG
    Health Aff (Millwood); 2008; 27(1):w34-40. PubMed ID: 18042561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The intersection of basic science and health policy: a conversation with Victor Velculescu. Interview by Barbara J. Culliton.
    Velculescu V
    Health Aff (Millwood); 2008; 27(1):w27-33. PubMed ID: 18042563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of cancer care: issues and implications.
    Meropol NJ; Schulman KA
    J Clin Oncol; 2007 Jan; 25(2):180-6. PubMed ID: 17210937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 7. Nanomedicine--the power of proteins: a conversation with Lance Liotta and Emanual Petricoin. Interview by Barbara J Culliton.
    Liotta L; Petricoin E
    Health Aff (Millwood); 2008; 27(4):w310-4. PubMed ID: 18559354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is special FDA regulation of nanomedicine needed? A conversation with Norris E. Alderson. Interview by Barbara J Culliton.
    Alderson NE
    Health Aff (Millwood); 2008; 27(4):w315-7. PubMed ID: 18559355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A conversation with Lee N. Newcomer, MD, MHA. Payments with purpose. Interview by John Marcille.
    Newcomer LN
    Manag Care; 2011 Dec; 20(12):36-40. PubMed ID: 22259875
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost of cancer care: the patient perspective.
    Kim P
    J Clin Oncol; 2007 Jan; 25(2):228-32. PubMed ID: 17210945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is high and growing spending on cancer treatment and prevention harmful to the United States economy?
    Pauly MV
    J Clin Oncol; 2007 Jan; 25(2):171-4. PubMed ID: 17210935
    [No Abstract]   [Full Text] [Related]  

  • 14. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.
    Yentzer BA; Yelverton CB; Simpson GL; Simpson JF; Hwang W; Balkrishnan R; Feldman SR
    Dermatol Online J; 2009 Apr; 15(4):1. PubMed ID: 19450394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
    Petrelli NJ; Winer EP; Brahmer J; Dubey S; Smith S; Thomas C; Vahdat LT; Obel J; Vogelzang N; Markman M; Sweetenham JW; Pfister D; Kris MG; Schuchter LM; Sawaya R; Raghavan D; Ganz PA; Kramer B
    J Clin Oncol; 2009 Dec; 27(35):6052-69. PubMed ID: 19901123
    [No Abstract]   [Full Text] [Related]  

  • 16. The medical expenditure panel survey: a national information resource to support healthcare cost research and inform policy and practice.
    Cohen JW; Cohen SB; Banthin JS
    Med Care; 2009 Jul; 47(7 Suppl 1):S44-50. PubMed ID: 19536015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The price of success: cost-effectiveness of molecularly targeted agents.
    Sleijfer S; Verweij J
    Clin Pharmacol Ther; 2009 Feb; 85(2):136-8. PubMed ID: 19151639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The burden of scientific progress: growing inequalities in the delivery of cancer care.
    Mano M
    Acta Oncol; 2006; 45(1):84-6. PubMed ID: 16464800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value-based reimbursement in oncology.
    Kolodziej M; Hoverman JR
    Am J Manag Care; 2012 May; 18(3 Spec No.):SP124-6. PubMed ID: 22642278
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
    Gralow J; Ozols RF; Bajorin DF; Cheson BD; Sandler HM; Winer EP; Bonner J; Demetri GD; Curran W; Ganz PA; Kramer BS; Kris MG; Markman M; Mayer RJ; Raghavan D; Ramsey S; Reaman GH; Sawaya R; Schuchter LM; Sweetenham JW; Vahdat LT; Davidson NE; Schilsky RL; Lichter AS;
    J Clin Oncol; 2008 Jan; 26(2):313-25. PubMed ID: 18086794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.